ArticleMolecular pharmaceutics2026
Probing Nanoscale Features of Electrospun Amorphous Solid Dispersions Using Advanced Biophysical Analysis.
Article in Molecular pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Amorphous solid dispersions (ASDs) can significantly enhance the solubility of poorly soluble active pharmaceutical ingredients (APIs). However, the typical thermodynamic instability of ASDs is a significant barrier to commercial success, and understanding API recrystallization behavior is crucial for enhancing stability. While most techniques do not allow the effective exploration of early-stage crystallization, small-angle neutron scattering (SANS) has shown promise in the study of nanoscale drug domains in polymer-drug composite materials. In this study, aspirin was incorporated in electrospun polycaprolactone (PCL) fibers at loadings from 10-30% w/w. Electron microscopy revealed the fibers to have smooth surfaces and diameters of 2-3 μm. X-ray diffraction and differential scanning calorimetry revealed the presence of crystalline drug at 20 and 30% loadings. Infrared spectroscopy indicated the presence of intermolecular interactions between the drug and the polymer; however, these interactions were insufficient to completely inhibit drug crystallization when the drug was supersaturated. SANS revealed heterogeneous nanoscale structures within the fibers, characterized by concentration-dependent drug-rich domains in the polymeric matrix. Their precise solid-state nature (amorphous versus crystalline) could not be determined by SANS, though X-ray diffraction indicated the presence of crystalline material at higher drug loadings. The SANS data also indicated the growth of drug aggregates after exposure to water. In vitro drug release tests suggested that the size of the drug domains could influence drug release behavior. Overall, this study provides a number of new insights into the crystallization of APIs in electrospun ASDs, which can be used to help guide the future development of more effective medicines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.